22nd Jan 2014 07:34
LONDON (Alliance News) - AstraZeneca PLC Wednesday said the Xigduo treatment it developed with Bristol-Myers Squibb as part of their diabetes collaboration, has been approved in the European Union as a treatment for Type 2 Diabetes.
Xigduo is indicated for adults aged 18 and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control. It is indicated in patients inadequately controlled on their current metformin-based treatment regimen or who are currently being treated with the combination of dapagliflozin and metformin as separate tablets, the drugs company said.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca